Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
28.82%
Operating Margin
-4.05%
Net Margin
-12.58%
Efficiency Metrics
Revenue per Expense Ratio
0.96
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
6.20%
Income Tax Rate
-227,300,000.0%
EPS
-1.2200000000
Balance Sheet Analysis
Current Ratio
0.88
Cash Ratio
0.09
Working Capital
$-77.88M
Debt to Equity
0.97
Debt to Assets
44.38%
Equity Ratio
45.95%
Cash Flow Analysis
Operating Cash Flow Ratio
13.70%
Free Cash Flow Ratio
1.34%
CapEx to Revenue
12.35%
Dividends Paid
$242.22M
Stock Buybacks
$3.38M
Total Shareholder Returns
$245.60M
Cash Position Change
13.81%
Key Takeaways (2023 FY)
Revenue declined by 8.2822623669047%, indicating potential market challenges
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
-8.28%
Net Income
-1,626.48%
EPS
-1,589.75%
Operating Income
-184.89%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-1.47%
Operating Cash Flow
22.05%
Free Cash Flow
256.50%
Balance Sheet Health
Assets
-2.90%
Debt
-2.51%
Book Value per Share
-6.21%
Inventory
4.85%
Shareholder Returns
Dividends per Share
-0.81%
Shares Outstanding
2.30%
Long Term Trends
3Y Revenue/Share
-0.87%
5Y Revenue/Share
-14.51%
3Y Dividend/Share
6.85%
5Y Dividend/Share
58.28%